Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: geminitherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2022 | $5.00 → $2.00 | Buy → Neutral | HC Wainwright & Co. |
| 3/3/2022 | $10.00 → $2.00 | Outperform → Market Perform | SVB Leerink |
| 3/1/2022 | $23.00 → $1.50 | Buy → Hold | Jefferies |
| 1/24/2022 | $15.00 → $10.00 | Outperform | SVB Leerink |
| 12/20/2021 | $25.00 → $15.00 | Outperform | SVB Leerink |
| 12/15/2021 | $20.00 | Buy | HC Wainwright & Co. |
| 10/6/2021 | $20.00 → $18.00 | Buy | Goldman Sachs |
Fastest customizable press release news feed in the world
WATERTOWN, Mass., Dec. 27, 2022 /PRNewswire/ -- Disc Medicine, Inc. ("Disc"), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that the U.S. Food and Drug Administration ("FDA") granted Orphan Drug Designation to bitopertin for the treatment of erythropoietic protoporphyria ("EPP"). Bitopertin is an investigational oral, selective inhibitor of glycine transporter 1 ("GlyT1") designed to modulate heme biosynthesis, and has been shown in preclinical studies to reduce accumulation of protoporphyrin IX ("PPIX"), the toxic metabolite that causes dise
WATERTOWN, Mass., Dec. 13, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients living with serious hematologic diseases, presented five posters spanning several of its hematology programs at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition held in New Orleans, LA. "Disc Medicine continues to make considerable progress towards the development of potentially first-in-class therapeutic candidates for hematologic disorders," said John
CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that five abstracts related to several of its hematology programs have been accepted for poster presentation at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in New Orleans, LA on December 10-13, 2022. "We are pleased to have five abstracts selected for presentat
AURORA study designed to evaluate bitopertin as a potential disease-modifying treatment for adults with EPP in the United StatesAURORA study designed to assess changes in protoporphyrin IX levels, safety, tolerability, photosensitivity and other measures in a double-blind, placebo-controlled setting; top-line data expected in 2023WATERTOWN, Mass., Oct. 31, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today the initiation of AURORA, a Phase 2 clinical study of bitopertin in adults with EPP. Bitopertin is an oral,
Merger to create NASDAQ-listed, clinical-stage biopharmaceutical company focused on advancing Disc Medicine's portfolio of hematology programs Combined company is expected to have approximately $175 million of cash or cash equivalents at close, including approximately $53.5 million from a concurrent financing restricted to Disc's existing investors, and which is expected to provide funding into 2025 Transaction will fund multiple clinical studies, including clinical trials of bitopertin for erythropoietic porphyrias, DISC-0974 for anemia of myelofibrosis, and DISC-0974 for anemia of chronic kidney disease Companies will host a joint webcast today, August 10, 2022 at 8:00 a.m. Eastern
Gemini Therapeutics, Inc. (NASDAQ:GMTX) today reported financial results for the year ended December 31, 2021. "As previously announced this year, Gemini Therapeutics has initiated a process to evaluate strategic options to maximize shareholder value that may potentially result in changes to our business strategy. While we have not set a timetable for completion of this strategic review process, we look forward to providing an update in the future if and when appropriate," said Georges Gemayel, Ph.D. Executive Chair and interim President and Chief Executive Officer. Full Year 2021 Financial Results Gemini reported a net loss of $71.9 million for the full year 2021 compared to $40.8 milli
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring. The Board of Directors has appointed Georges Gemayel, Ph.D., the Company's current Executive Chair, as interim President and Chief Executive Officer to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company. Additionally, the Company has initiated a process to evaluate strategic alternatives in order
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103's clinical development program. GEM103 Phase 2a ReGAtta Study Update Ongoing analysis of the 62 patients enrolled in the ReGAtta study continues to show that more than nine months of GEM103 exposure has been generally well-tolerated, able to durably reduce biomarkers of complement activation, and able to maintain supraphysiological levels of Complement Factor H (CFH). ReGAtta, an open-label, non-cont
GEM103 updated safety information presented during AAO including no increased risk for CNV observed to date in ongoing ReGAtta Phase 2a study Expect to provide six-month update from GEM103 ReGAtta study by year-end Scheduled to meet with the FDA in 4Q'21 and expect to initiate late-stage trial for GEM103 in patients with GA in 1Q'22 Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD) today reported its financial results for the third quarter ended September 30, 2021 and provided a business update. "This weekend at the American Academy of Ophthalmology (AAO) an
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced that Raj Maturi, M.D., Adjunct Clinical Assistant Professor of Ophthalmology at Indiana University School of Medicine and an investigator in the ReGAtta study, will present a poster at the 2021 Annual Meeting of the American Academy of Ophthalmology (AAO), which is being held virtually and in-person at the Ernest N. Morial Convention Center, New Orleans, LA on November 12 – 15, 2021. Details of the virtual poster at the AAO meeting include: Title: Phase 2a Open Label Study of GEM103 in Genetica
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Disc Medicine, Inc. (0001816736) (Issuer)
3 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
8-K - Disc Medicine, Inc. (0001816736) (Filer)
144 - Disc Medicine, Inc. (0001816736) (Subject)
144 - Disc Medicine, Inc. (0001816736) (Subject)
144 - Disc Medicine, Inc. (0001816736) (Subject)
144 - Disc Medicine, Inc. (0001816736) (Subject)
144/A - Disc Medicine, Inc. (0001816736) (Subject)
144/A - Disc Medicine, Inc. (0001816736) (Subject)
144/A - Disc Medicine, Inc. (0001816736) (Subject)
144 - Disc Medicine, Inc. (0001816736) (Subject)
144 - Disc Medicine, Inc. (0001816736) (Subject)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
HC Wainwright & Co. downgraded Gemini Therapeutics from Buy to Neutral and set a new price target of $2.00 from $5.00 previously
SVB Leerink downgraded Gemini Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $10.00 previously
Jefferies downgraded Gemini Therapeutics from Buy to Hold and set a new price target of $1.50 from $23.00 previously
SVB Leerink reiterated coverage of Gemini Therapeutics with a rating of Outperform and set a new price target of $10.00 from $15.00 previously
SVB Leerink reiterated coverage of Gemini Therapeutics with a rating of Outperform and set a new price target of $15.00 from $25.00 previously
HC Wainwright & Co. initiated coverage of Gemini Therapeutics with a rating of Buy and set a new price target of $20.00
Goldman Sachs reiterated coverage of Gemini Therapeutics with a rating of Buy and set a new price target of $18.00 from $20.00 previously
SVB Leerink initiated coverage of Gemini Therapeutics with a rating of Outperform and set a new price target of $25.00
Live Leadership Updates
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring. The Board of Directors has appointed Georges Gemayel, Ph.D., the Company's current Executive Chair, as interim President and Chief Executive Officer to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company. Additionally, the Company has initiated a process to evaluate strategic alternatives in order
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Georges Gemayel, Ph. D., as the Chair of the Company's Board of Directors. "I am pleased to welcome Georges to Gemini's Board of Directors during this important time in our Company's maturation, as we advance our lead program into the next stages of clinical development," said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. "Georges' broad management experience and proven track record of commercial and product development success wi
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini's Chief Medical Officer, effective immediately. "We are thrilled to welcome Sam to Gemini as Chief Medical Officer, where he will bring his expertise as a board-certified ophthalmologist specializing in the treatment of retinal and macular diseases," said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. "As we continue to advance our clinical pipeline, we will benefit tremendously from his two-plus deca
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today reported its financial results for the year ended December 31, 2020 and provided a business update. “The past 12 months have been truly transformative for Gemini as we successfully transitioned to a publicly traded precision medicine company with a strong balance sheet and resources to advance to important clinical milestones,” said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics, Inc. “The successful completion of the Phase 1 study provided en
This live feed shows all institutional transactions in real time.
SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13D/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13D/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13D/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13G - Disc Medicine, Inc. (0001816736) (Subject)
SC 13D/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13G - Disc Medicine, Inc. (0001816736) (Subject)